PCF - Department of Defense Prostate Cancer Clinical Trials Consortium (PCCTC) Trials
Rising PSA Without Prior Hormonal Therapy
Phase 2 Multimodality Therapy (Docetaxel and Sunitinib) for Recurrent High Risk Prostate Cancer
This Phase II trial will evaluate the safety, tolerability, and possible effect of 37.5 mg of sunitinib (Sutent®) administered daily along with 70 mg/m2 docetaxel administered every 3 weeks to 38 high-risk, non-metastatic prostate cancer patients who experienced PSA relapse after radical prostatectomy. Potential activity of the treatment will be measured by standard prostate-specific antigen (PSA) tests. The concurrent use of sunitinib with docetaxel may provide additional systemic control to this high risk population.
Participating PCCTC Sites: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Duke University; Cancer Institute of New Jersey
For more information, go to:
http://clinicaltrials.gov/ct2/show/NCT00734851?term=docetaxel+and+sunitinib&rank=10
Randomized Phase II Trial of Short-course Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer after Definitive Local Therapy
This Phase II unblinded, randomized trial will identify a difference in relapse free survival in 100 rising PSA, non-castrate prostate cancer patients given 6 months of Androgen deprivation therapy with or without 15 mg/kg Bevacizumab administered every 3 weeks.
Participating PCCTC Sites: Memorial Sloan-Kettering Cancer Center; Dana-Farber Harvard Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; MD Anderson Cancer Center; University of Wisconsin; Cancer Institute of New Jersey
For more information, go to:
http://clinicaltrials.gov/ct2/show/NCT00776594?term=Randomized+Phase+II+trial+of+short-course+androgen+deprivation+therapy+%2B%2F-+bevacizumab&rank=1
Multicenter, Double-blind Study Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Intermittent Androgen Ablation Therapy for Prostate Cancer
This Phase II double-blind, randomized trial will evaluate the safety, tolerability, and possible effect of 0.5 mg dutasteride administered daily to prolong the off treatment interval of patients with localized prostate cancer receiving intermittent androgen ablation therapy for a rising PSA post-radiation or post-prostatectomy. Potential activity of the treatment will be measured by standard prostate-specific antigen (PSA) tests.
Participating PCCTC Sites: Oregon Health and Science University; University of Washington
For more information, go to:
http://clinicaltrials.gov/ct2/show/NCT00553878?term=Multicenter%2C+double-blind+study+comparing+0.5+mg+dutasteride+vs+placebo+daily+in+men+receiving+intermittent+androgen+ablation&rank=1
A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy
The Phase II randomized trial will evaluate the safety, tolerability, and possible effect of GW786034 (Pazopanib) on time to progression following 6 months of androgen blockade in non-metastatic, stage D0 prostate cancer. Potential activity of the treatment will be measured by standard prostate-specific antigen (PSA) tests. It is hypothesized that the use of pazopanib in this patient population will modulate pro-survival and pro-angiogenic signals resulting in an increase in time to PSA progression following therapy.
Participating PCCTC Sites: University of Michigan; University of Wisconsin; University of Chicago
For more information, go to:
http://clinicaltrials.gov/ct2/show/NCT00454571?term=A+Randomized%2C+Phase+II+Study+of+GW786034+%28Pazopanib%29+in+Stage+D0+Relapsed&rank=1
For the full listing of trials, click here.
| 
